

Fabrizio Schifano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4396406/fabrizio-schifano-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

2,770
citations

29
h-index

49
g-index

118
ext. papers

3,504
ext. citations

4.3
avg, IF

5.93
L-index

#	Paper	IF	Citations
99	Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study.. <i>PLoS ONE</i> , 2022 , 17, e0262704	3.7	1
98	A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. <i>Pharmaceuticals</i> , 2022 , 15, 565	5.2	0
97	Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). <i>Pharmaceuticals</i> , 2022 , 15, 675	5.2	0
96	Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. <i>Frontiers in Psychiatry</i> , 2021 , 12, 640218	5	5
95	Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany. <i>Frontiers in Psychiatry</i> , 2021 , 12, 648273	5	6
94	The e-psychoactive drugs' psychopharmacology. <i>Current Opinion in Pharmacology</i> , 2021 , 57, 165-174	5.1	4
93	Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. <i>Frontiers in Psychiatry</i> , 2021 , 12, 657397	5	9
92	New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. <i>Experimental Neurology</i> , 2021 , 339, 113638	5.7	9
91	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	2
90	The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
89	COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. <i>Brain Sciences</i> , 2021 , 11,	3.4	2
88	Substance-related exogenous psychosis: a postmodern syndrome. <i>CNS Spectrums</i> , 2021 , 26, 84-91	1.8	20
87	Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 230-237	1.9	1
86	Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. <i>Journal of Psychopharmacology</i> , 2021 , 35, 681-692	4.6	5
85	Opioid painkiller dependence in a sample of elderly medical inpatients. <i>Psychogeriatrics</i> , 2021 , 21, 265-271	1.8	2
84	The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. <i>Brain Sciences</i> , 2021 , 11,	3.4	13
83	Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise. <i>European Neuropsychopharmacology</i> , 2021 , 49, 69-92	1.2	5

82	Worsening of the Toxic Effects of (±)-4,4'-DMAR Following Its Co-Administration with (±)-4,4'-DMAR: Neuro-Behavioural, Physiological, Immunohistochemical and Metabolic Studies in Mice. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
81	Novel Opioids: Systematic Web Crawling Within the e-Psychnauts' Scenario. <i>Frontiers in Neuroscience</i> , 2020 , 14, 149	5.1	13
80	Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. <i>Brain Sciences</i> , 2020 , 10,	3.4	10
79	Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. <i>Brain Sciences</i> , 2020 , 10,	3.4	4
78	Anabolic androgenic steroid abuse in the United Kingdom: An update. <i>British Journal of Pharmacology</i> , 2020 , 177, 2180-2198	8.6	20
77	'New/Designer Benzodiazepines': An Analysis of the Literature and Psychnauts' Trip Reports. <i>Current Neuropharmacology</i> , 2020 , 18, 809-837	7.6	21
76	The e-Psychnauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online. <i>Current Neuropharmacology</i> , 2020 , 18, 966-1051	7.6	8
75	What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media. <i>Current Neuropharmacology</i> , 2020 , 18, 906-917	7.6	4
74	Prescription Drug Misuse in "Clubbers" and Disco Goers in Ibiza. <i>Frontiers in Psychiatry</i> , 2020 , 11, 5925945		3
73	The clinical challenges of synthetic cathinones. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 410-419	3.8	29
72	How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 482-498	3.8	13
71	The Psychnauts' World of Cognitive Enhancers. <i>Frontiers in Psychiatry</i> , 2020 , 11, 546796	5	9
70	Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients. <i>Frontiers in Psychiatry</i> , 2020 , 11, 879	5	4
69	Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020 , 10,	2.3	5
68	COVID-19: The Hidden Impact on Mental Health and Drug Addiction. <i>Frontiers in Psychiatry</i> , 2020 , 11, 767	5	51
67	Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?. <i>Frontiers in Psychiatry</i> , 2020 , 11, 598150	5	2
66	Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review. <i>Substance Use and Misuse</i> , 2020 , 55, 304-313	2.2	7
65	Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 505-516	3.8	6

64	Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. <i>Frontiers in Psychiatry</i> , 2020 , 11, 632405	5	11
63	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 1253-1264	4.3	8
62	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. <i>Current Addiction Reports</i> , 2019 , 6, 140-152	3.9	7
61	Pregabalin: A range of misuse-related unanswered questions. <i>CNS Neuroscience and Therapeutics</i> , 2019 , 25, 659-660	6.8	17
60	An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 270-277	5.8	45
59	Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. <i>Frontiers in Pharmacology</i> , 2019 , 10, 46	5.6	32
58	Cannabidiol (CBD) use in psychiatric disorders: A systematic review. <i>NeuroToxicology</i> , 2019 , 74, 282-298	4.4	59
57	The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. <i>Frontiers in Psychiatry</i> , 2019 , 10, 851	5	9
56	β ₂ Agonists as Misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency Pharmacovigilance Database Reports. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 123, 182-187	3.1	16
55	Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. <i>Brain Sciences</i> , 2018 , 8,	3.4	9
54	Is There a Potential of Misuse for Venlafaxine and Bupropion?. <i>Frontiers in Pharmacology</i> , 2018 , 9, 239	5.6	18
53	Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2018 , 9, 153	5	8
52	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. <i>Brain Sciences</i> , 2018 , 8,	3.4	34
51	Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues. <i>Brain Sciences</i> , 2018 , 8,	3.4	26
50	Joint versus separate inpatient rehabilitation treatment for patients with alcohol use disorder or drug use disorder: an observational study. <i>Substance Abuse and Rehabilitation</i> , 2018 , 9, 23-29	5.5	1
49	Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom Communities Associated with GHB and Precursors. <i>Current Drug Metabolism</i> , 2018 , 19, 1086-1099	3.5	17
48	Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice. <i>Frontiers in Psychiatry</i> , 2018 , 9, 575	5	10
47	Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. <i>PLoS ONE</i> , 2018 , 13, e0204443	3.7	22

46	An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS). <i>Human Psychopharmacology</i> , 2017 , 32, e2581	2.3	49
45	Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. <i>Human Psychopharmacology</i> , 2017 , 32, e2578	2.3	50
44	A matter of life and death: substance-caused and substance-related fatalities in Ibiza in 2015. <i>Human Psychopharmacology</i> , 2017 , 32, e2592	2.3	9
43	Is there a potential of misuse for <i>Magnolia officinalis</i> compounds/metabolites?. <i>Human Psychopharmacology</i> , 2017 , 32, e2595	2.3	9
42	Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza. <i>Human Psychopharmacology</i> , 2017 , 32, e2586	2.3	18
41	NPS: Medical Consequences Associated with Their Intake. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 32, 351-380	3.4	21
40	Intended and unintended use of cathinone mixtures. <i>Human Psychopharmacology</i> , 2017 , 32, e2598	2.3	32
39	An insight into the deep web; why it matters for addiction psychiatry?. <i>Human Psychopharmacology</i> , 2017 , 32, e2573	2.3	34
38	4,4'-Dimethylaminorex ("4,4'-DMAR"; "Serotoni") misuse: A Web-based study. <i>Human Psychopharmacology</i> , 2017 , 32, e2575	2.3	12
37	Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?. <i>Current Neuropharmacology</i> , 2017 , 15, 731-737 ^{7.6}	7.6	14
36	The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. <i>Frontiers in Psychiatry</i> , 2017 , 8, 240	5	46
35	Herbal Highs: Review on Psychoactive Effects and Neuropharmacology. <i>Current Neuropharmacology</i> , 2017 , 15, 750-761	7.6	25
34	When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex". <i>Current Neuropharmacology</i> , 2017 , 15, 762-770	7.6	85
33	Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics' ("Spice") Intake?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 585-591	2.6	10
32	Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 598-609	2.6	21
31	The potential utility of some legal highs in CNS disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 64, 267-74	5.5	10
30	The consequences of drug misuse on post-marketing surveillance. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 867-71	3.8	9
29	A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. <i>CNS Drugs</i> , 2016 , 30, 647-54	6.7	90

28	Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 943-54	3.8	34
27	Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. <i>Neuropharmacology</i> , 2016 , 105, 630-638	5.5	56
26	A systematic review of the nature of dispensing errors in hospital pharmacies. <i>Integrated Pharmacy Research & Practice</i> , 2016 , 5, 1-10	4.4	24
25	Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths. <i>Addictive Behaviors</i> , 2016 , 60, 53-7	4.2	1
24	Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2015 , 18, 296-300	4.4	54
23	Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 53, 52-78	9	62
22	Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012). <i>Journal of Epidemiology and Global Health</i> , 2015 , 5, 385-95	5.5	16
21	Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. <i>Human Psychopharmacology</i> , 2015 , 30, 249-54	2.3	26
20	Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences. <i>Human Psychopharmacology</i> , 2015 , 30, 255-61	2.3	10
19	Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. <i>Human Psychopharmacology</i> , 2015 , 30, 302-18	2.3	47
18	Novel psychoactive substances of interest for psychiatry. <i>World Psychiatry</i> , 2015 , 14, 15-26	14.4	211
17	Misuse and abuse of pregabalin and gabapentin: cause for concern?. <i>CNS Drugs</i> , 2014 , 28, 491-6	6.7	148
16	Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. <i>International Journal of Drug Policy</i> , 2014 , 25, 724-6	5.5	47
15	25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. <i>BioMed Research International</i> , 2014 , 2014, 734749	3	64
14	Substance use in the club scene of Rome: a pilot study. <i>BioMed Research International</i> , 2014 , 2014, 617546	3	64
13	Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba. <i>BioMed Research International</i> , 2014 , 2014, 841798	3	40
12	e-Psychonauts: conducting research in online drug forum communities. <i>Journal of Mental Health</i> , 2012 , 21, 386-94	2.7	102
11	Impact of an 18-month, NHS-based, treatment exposure for heroin dependence: results from the London Area Treat 2000 Study. <i>American Journal on Addictions</i> , 2012 , 21, 268-73	3.7	7

10	Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 710-4	1.7	88
9	Bundle of fun or Bunch of problems? Case series of khat-related deaths in the UK. <i>Drugs: Education, Prevention and Policy</i> , 2011 , 18, 408-425	1.2	23
8	Drug Abuse: Treatment and Management 2011 , 53-74		3
7	Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. <i>Psychopharmacology</i> , 2011 , 214, 593-602	4.7	246
6	Psychoactive drug or mystical incense? Overview of the online available information on Spice products. <i>International Journal of Culture and Mental Health</i> , 2009 , 2, 137-144		49
5	Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990 - 2004). <i>Journal of Psychopharmacology</i> , 2008 , 22, 71-9	4.6	30
4	Recreational Drugs' Scenario and Compulsory Treatment in the United Kingdom. <i>International Journal of Mental Health</i> , 2008 , 37, 22-56	1.4	
3	Is urbanization a risk factor for substance misuse?. <i>Current Opinion in Psychiatry</i> , 2008 , 21, 391-7	4.9	7
2	Personality dimensions and psychopathological profiles of Ecstasy users. <i>Human Psychopharmacology</i> , 2001 , 16, 635-639	2.3	50
1	Knowledge and Use of Novel Psychoactive Substances in Italy: a Survey-Based Study in the General Population. <i>International Journal of Mental Health and Addiction</i> , 1	8.8	